pSivida boosts US focus
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Tuesday, 2 August, 2005 - 22:00
Perth-based nanotechnology company pSivida Limited has appointed two new non-executive directors, both based in the United States. David Mazzo is currently president and chief executive officer of Chugai Pharma USA, while Michael Rogers is executive vice-president and chief financial officer of Indevus Pharmaceuticals Incorporated.The two appointments reflect the increased visibility of pSivida in the US market, following their NASDAQ listing earlier this year. The company has also become a founding member of NASDAQ’s new health care index.